Assembly Biosciences, Inc.

ASMB

US0453962070

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:30:00 2024-06-06 pm EDT			5-day change	1st Jan Change
15.41 ^USD	+0.72%		+3.70%	+56.59%

Jun. 05	Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor Abi-6250 At the Easl Congress 2024	CI
May. 08	Assembly Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Assembly Biosciences, Inc. Announces Resignation of Michael Samar as Chief Financial Officer, Effective August 12, 2022

July 20, 2022 at 04:05 pm EDT

Assembly Biosciences, Inc. announced that Michael Samar, currently the chief financial officer, will leave the organization effective August 12, 2022.

Latest news about Assembly Biosciences, Inc.

Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor Abi-6250 At the Easl Congress 2024	Jun. 05	CI
Assembly Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Assembly Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Assembly Biosciences Insider Bought Shares Worth $511,264, According to a Recent SEC Filing	Jan. 19	MT
Assembly Biosciences, Inc. Provides Anticipated Development Milestones for 2024	Jan. 04	CI
Assembly Biosciences, Inc. Appoints Tomas Cihlar to Serve on the Board	Dec. 07	CI
Assembly Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Assembly Biosciences, Inc. Appoints Anuj Gaggar as Chief Medical Officer	Nov. 08	CI
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday	23-10-17	MT
Sector Update: Health Care	23-10-17	MT
Assembly Biosciences Shares Soar Premarket on Gilead Pact	23-10-17	DJ
Transcript : Assembly Biosciences, Inc., Gilead Sciences, Inc. - Special Call	23-10-17
Gilead Sciences, Assembly Biosciences Working Together to Accelerate Development of New Antiviral Therapies	23-10-17	MT
Gilead Taking Stake in Assembly Bio Under Antiviral Collaboration	23-10-17	DJ
Gilead Sciences, Inc. and Assembly Biosciences, Inc. Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases	23-10-17	CI
Assembly Biosciences, Inc. announced that it expects to receive $15.165455 million in funding from Gilead Sciences, Inc.	23-10-14	CI
Assembly Biosciences Nominates Development Candidate Abi-6250, an Orally Bio Available HDV Entry Inhibitor	23-10-02	CI
Assembly Biosciences, Inc. to Present Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting	23-09-19	CI
Assembly Biosciences, Inc.(NasdaqGS:ASMB) dropped from S&P Global BMI Index	23-09-18	CI
Assembly Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Assembly Biosciences, Inc. Presents New Data Highlighting Herpes Simplex Virus Development Candidate Abi-5366 At the 47Th Annual International Herpesvirus Workshop	23-07-17	CI
Assembly Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Assembly Biosciences Announces Additional Promising Data from Phase 1A Clinical Trial Evaluating Highly Potent Next-Generation Core Inhibitor Candidate Abi-4334 and Provides Pipeline Update	23-04-18	CI
HC Wainwright Adjusts Price Target on Assembly Biosciences to $1.50 From $2.50, Keeps Neutral Rating	23-03-24	MT
Assembly Biosciences Files $150 Million Mixed Shelf	23-03-23	MT

Chart Assembly Biosciences, Inc.

Duration

Period

More charts

Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small molecule antiviral therapeutics. The Companyâs pipeline includes two helicase-primase inhibitors (HPI) targeting recurrent genital herpes, an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, a clinical-stage capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points with the aim of achieving finite treatment and functional cures and research programs focused on the discovery of therapeutics to treat devastating viral diseases, including a non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses and a small molecule interferon-Î± (IFN-Î±) receptor (IFNAR) agonist targeting HBV and HDV. HPIs are antiviral agents in development for HSV-1 and HSV-2, with a clinically validated mechanism of action. Its HBV, HSV-1, and HSV-2 programs include ABI-6250, ABI-5366, and ABI-1179.

Sector

Pharmaceuticals

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Assembly Biosciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

15.41 USD

Average target price

36 USD

Spread / Average Target

+133.61%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
ASSEMBLY BIOSCIENCES, INC.	+56.59%	84.96M
MERCK KGAA	+19.29%	81.33B
KYOWA KIRIN CO. LTD.	+14.11%	9.14B
SK BIOPHARMACEUTICALS CO., LTD.	-15.14%	4.89B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+46.88%	4.61B
YUHAN CORPORATION	+15.70%	4.36B
INDIVIOR PLC	+10.89%	2.26B
BETTA PHARMACEUTICALS CO., LTD.	-27.88%	2.15B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+15.73%	2.1B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-43.02%	1.78B

Specialty & Advanced Pharmaceuticals